News

Rise’s R-2487 moves toward clinical testing as Sjögren’s treatment

Rise Therapeutics plans to launch a Phase 1 clinical trial testing R-2487, its experimental oral therapy for autoimmune diseases, in people with Sjögren’s disease. R-2487, which leverages bacterial proteins to suppress the abnormal immune responses in autoimmune diseases like Sjögren’s, “is disease-modifying, focusing on long-term immune correction rather…

B-cells containing CD226 may be Sjögren’s biomarker, therapy target

Immune B-cells that contain the receptor protein CD226 may play a role in the development and clinical manifestations of primary Sjögren’s disease, making CD226 a possible target for future treatments, a study reports. Data indicated that people with Sjögren’s had proportionally more CD226-positive B-cells in their bloodstream than their…

Traditional Chinese medicine QJZG may help ease Sjögren’s disease

A traditional Chinese medicine formulation called Qihuang Jianpi ZiShen Granule (QJZG) may help to alleviate Sjögren’s disease by reducing inflammatory molecules and associated tissue damage, according to computer simulations and tests in a cell model of the disease. “This study provides evidence supporting the use of Chinese medicine…